当前位置: 首页 >> 检索结果
6441. Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension.
作者: Felix Mahfoud.;Horst Sievert.;Stefan Bertog.;Lucas Lauder.;Sebastian Ewen.;Jean-Philippe Lengelé.;Wojciech Wojakowski.;Roland Schmieder.;Markus van der Giet.;Michael A Weber.;David E Kandzari.;Helen Parise.;Tim A Fischell.;Atul Pathak.;Alexandre Persu.
来源: Circ Cardiovasc Interv. 2021年14卷9期e010075页
[Figure: see text].
6442. Letter by Moroni et al Regarding Article, "Feasibility and Safety of High-Risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support".6444. Left Ventricular Pseudoaneurysm Caused by Radiofrequency Catheter Ablation: From Diagnosis to Treatment With Multimodality Imaging.
作者: Joseph Nicolazzi.;John Grizzard.;Vigneshwar Kasirajan.;Kenneth Ellenbogen.;Roshanak Markley.
来源: Circ Cardiovasc Imaging. 2021年14卷9期e012820页 6445. Cryoballoon Versus High-Power, Short-Duration Radiofrequency Ablation for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation: A Single-Center, Prospective, Randomized Study.
作者: Hui-Nam Pak.;Je-Wook Park.;Song-Yi Yang.;Tae-Hoon Kim.;Jae-Sun Uhm.;Boyoung Joung.;Moon-Hyoung Lee.;Hee Tae Yu.
来源: Circ Arrhythm Electrophysiol. 2021年14卷9期e010040页
[Figure: see text].
6446. Stress and Coping Among Family Caregivers of Patients With a Destination Therapy Left Ventricular Assist Device: A Multicenter Mixed Methods Study.
作者: Colleen K McIlvennan.;Jacqueline Jones.;Marybeth Makic.;Paula M Meek.;Erin Chaussee.;Jocelyn S Thompson.;Daniel D Matlock.;Larry A Allen.
来源: Circ Heart Fail. 2021年14卷10期e008243页
Family caregivers of patients with a destination therapy left ventricular assist device play a central and formalized role in postimplant care. We aimed to characterize longitudinal stress, predictors and correlates of stress, and coping processes among left ventricular assist device caregivers.
6447. Contemporary Patients With Congenital Heart Disease: Uniform Atrial Tachycardia Substrates Allow for Clear Ablation Endpoints With Improved Long-Term Outcome.
作者: Charlotte Brouwer.;Joachim Hebe.;Peter Lukac.;Jan-Hendrik Nürnberg.;Jens Cosedis Nielsen.;Marta de Riva Silva.;Nico Blom.;Mark Hazekamp.;Katja Zeppenfeld.
来源: Circ Arrhythm Electrophysiol. 2021年14卷9期e009695页
[Figure: see text].
6449. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction.
作者: Aya F Ozaki.;Harlan M Krumholz.;Freny Vaghaiwalla Mody.;Tien T Tran.;Quan T Le.;Mai Yokota.;Cynthia A Jackevicius.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷9期e007665页
Slow uptake of sacubitril/valsartan in patients with heart failure with reduced ejection fraction has been reported, which may negatively impact clinical outcomes. We characterized prior authorization (PA) burden, prescription copayment, and utilization of sacubitril/valsartan by insurance plan type to identify potential barriers to its use.
6450. Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure.
作者: Vittal Hejjaji.;Yuanyuan Tang.;Theresa Coles.;Philip G Jones.;Bryce B Reeve.;Robert J Mentz.;Erica S Spatz.;Shannon M Dunlay.;Brittany Caldwell.;Anindita Saha.;Michelle E Tarver.;Andy Tran.;Krishna K Patel.;Debra Henke.;Ileana L Piña.;John A Spertus.
来源: Circ Heart Fail. 2021年14卷9期e008284页
The Kansas City Cardiomyopathy Questionnaire (KCCQ) has been psychometrically evaluated in multiple heart failure (HF) populations, but the comparability of its psychometric properties between men and women is unknown.
6452. Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults.
作者: Quinn S Wells.;Minoo Bagheri.;Aaron W Aday.;Deepak K Gupta.;Christian M Shaffer.;Wei-Qi Wei.;Nataraja Sarna Vaitinadin.;Sadiya S Khan.;Philip Greenland.;Thomas J Wang.;C Michael Stein.;Dan M Roden.;Jonathan D Mosley.
来源: Circ Genom Precis Med. 2021年14卷5期e003341页
Polygenic risk scores (PRS) may enhance risk stratification for coronary heart disease among young adults. Whether a coronary heart disease PRS improves prediction beyond modifiable risk factors in this population is not known.
6453. Predictive Accuracy of a Clinical and Genetic Risk Model for Atrial Fibrillation.
作者: Shaan Khurshid.;Nina Mars.;Christopher M Haggerty.;Qiuxi Huang.;Lu-Chen Weng.;Dustin N Hartzel.; .;Kathryn L Lunetta.;Jeffrey M Ashburner.;Christopher D Anderson.;Emelia J Benjamin.;Veikko Salomaa.;Patrick T Ellinor.;Brandon K Fornwalt.;Samuli Ripatti.;Ludovic Trinquart.;Steven A Lubitz.
来源: Circ Genom Precis Med. 2021年14卷5期e003355页
Atrial fibrillation (AF) risk estimation using clinical factors with or without genetic information may identify AF screening candidates more accurately than the guideline-based age threshold of ≥65 years.
6455. Genotype-Phenotype Correlation of SCN5A Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands.
作者: Anat Milman.;Elijah R Behr.;Belinda Gray.;David C Johnson.;Antoine Andorin.;Aviram Hochstadt.;Jean-Baptiste Gourraud.;Shingo Maeda.;Yoshihide Takahashi.;Jimmy Jm Juang.;Sung-Hwan Kim.;Tsukasa Kamakura.;Takeshi Aiba.;Pieter G Postema.;Yuka Mizusawa.;Isabelle Denjoy.;Carla Giustetto.;Giulio Conte.;Zhengrong Huang.;Georgia Sarquella-Brugada.;Andrea Mazzanti.;Camilla H Jespersen.;Elena Arbelo.;Ramon Brugada.;Leonardo Calo.;Domenico Corrado.;Ruben Casado-Arroyo.;Giuseppe Allocca.;Masahiko Takagi.;Pietro Delise.;Josep Brugada.;Jacob Tfelt-Hansen.;Silvia G Priori.;Christian Veltmann.;Gan-Xin Yan.;Pedro Brugada.;Fiorenzo Gaita.;Antoine Leenhardt.;Arthur A M Wilde.;Kengo F Kusano.;Gi-Byoung Nam.;Kenzo Hirao.;Vincent Probst.;Bernard Belhassen.
来源: Circ Genom Precis Med. 2021年14卷5期e003222页
Brugada syndrome (BrS) is associated with mutations in the cardiac sodium channel gene, SCN5A. However, genetic studies of patients with BrS with arrhythmic events have been limited. We sought to compare various clinical, ECG, and electrophysiological parameters according to SCN5A genotype in a large cohort of BrS probands with first arrhythmic event.
6456. The Propagation of Racial Disparities in Cardiovascular Genomics Research.
作者: Shoa L Clarke.;Themistocles L Assimes.;Catherine Tcheandjieu.
来源: Circ Genom Precis Med. 2021年14卷5期e003178页
Genomics research has improved our understanding of the genetic basis for human traits and diseases. This progress is now being translated into clinical care as we move toward a future of precision medicine. Many hope that expanded use of genomic testing will improve disease screening, diagnosis, risk stratification, and treatment. In many respects, cardiovascular medicine is leading this charge. However, most cardiovascular genomics research has been conducted in populations of primarily European ancestry. This bias has critical downstream effects. Here, we review the current disparities in cardiovascular genomics research, and we outline how these disparities propagate forward through all phases of the translational pipeline. If not adequately addressed, biases in genomics research will further compound the existing health disparities that face underrepresented and marginalized populations.
6457. Genome-Wide Association Meta-Analysis Supports Genes Involved in Valve and Cardiac Development to Associate With Mitral Valve Prolapse.
作者: Mengyao Yu.;Sergiy Kyryachenko.;Stephanie Debette.;Philippe Amouyel.;Jean-Jacques Schott.;Thierry Le Tourneau.;Christian Dina.;Russell A Norris.;Albert A Hagège.;Xavier Jeunemaitre.;Nabila Bouatia-Naji.
来源: Circ Genom Precis Med. 2021年14卷5期e003148页
Mitral valve prolapse (MVP) is a common cardiac valve disease, which affects 1 in 40 in the general population. Previous genome-wide association study has identified 6 risk loci for MVP. But these loci explained only partially the genetic risk for MVP. We aim to identify additional risk loci for MVP by adding data set from the UK Biobank.
6458. Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study.
作者: Johan Larsson.;Søren L Kristensen.;Christian Madelaire.;Morten Schou.;Kasper Rossing.;Søren Boesgaard.;Lars Køber.;Finn Gustafsson.
来源: Circ Heart Fail. 2021年14卷10期e008662页
Factors determining referral for advanced heart failure (HF) evaluation are poorly studied. We studied the influence of socioeconomic aspects on the referral process in Denmark, which has a taxpayer-funded national health care system.
6460. Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure.
作者: Nisha A Gilotra.;Adam D DeVore.;Thomas J Povsic.;Allison G Hays.;Virginia S Hahn.;Tolu A Agunbiade.;Allison DeLong.;Andrew Satlin.;Richard Chen.;Robert Davis.;David A Kass.
来源: Circ Heart Fail. 2021年14卷9期e008236页
PDE1 (phosphodiesterase type 1) hydrolyzes cyclic adenosine and guanosine monophosphate. ITI-214 is a highly selective PDE1 inhibitor that induces arterial vasodilation and positive inotropy in larger mammals. Here, we assessed pharmacokinetics, hemodynamics, and tolerability of single-dose ITI-214 in humans with stable heart failure with reduced ejection fraction.
|